This episode examines the FDA’s approval of expanded operator permissions for electrical impedance spectroscopy in dermatology, the over seven thousand comment submissions to HHS on clinical AI regulation, a state legislative draft introducing the AI Medical Services Provider entity category with tiered risk classification and mandatory coverage, deployment data showing seventy percent of healthcare organizations actively using AI, the University of Mississippi Medical Center ransomware incident, and the FDA’s draft pathway for single patient gene therapies under plausible mechanism review. The briefing provides operational context on how regulatory frameworks are being constructed in parallel with live clinical deployments, addressing workflow delegation, reimbursement structures, and approval criteria adjustments across diagnostic devices, algorithmic service delivery, and ultra rare disease therapeutics.
